In QuotedData’s morning briefing 3 July 2025: JPMorgan Global Growth and Income dividend to rise. Crystal Amber’s Morphic Medical gets EU approval.
- JPMorgan Global Growth and Income (JGGI) has decided on its dividend for the financial year ended 30 June 2026. There will be four quarterly payments of 5.75p to make a total of 23.0p, that is 0.9% higher than FY25’s dividend. The dividend is supposed to be based on 4% of the financial year end NAV, which fell by 3.1% year-on-year. However, the board wants to keep growing the dividend and the percentage will be a bit higher this year. [QD comment, James Carthew: So, JGGI gets to keep its record of dividend growth despite a fall in its NAV. The numbers here are too small to worry about, but, what would happen next year if the NAV falls again?]
- Crystal Amber (CRS) says its Morphic Medical subsidiary has secured European regulatory approval for its non-surgical, non-drug obesity and diabetes treatment. [QD comment, James Carthew: I cannot help thinking that the potential market for this is massively smaller than it was a couple of years ago, before the rapid growth in weight-loss drugs.]
We also have:
Did you see from yesterday?
